Skip to Content

NDT Pharmaceuticals Inc NDTP

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

NDT Pharmaceuticals Inc is a biotechnology company focused on developing revolutionary therapies for severe neurological disorders associated with traumatic brain injury. Its Nanoscale Particle Complex (NPC) technology represents the leading edge of phospholipid-based nano-encapsulation delivery systems (less than 100 nanometers in diameter; mean diameter of 40 nanometers in current liquid product samples with the capability to engineer significantly smaller nanocarrier particles) that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth.

8616 Westwood Center Drive, Suite 314
Vienna, VA, 22182
T +1 571 581-7986
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2008
Fiscal Year End Dec 31, 2021
Stock Type Distressed